Sun Pharmaceutical Industries launches LEQSELVI (deuruxolitinib) 8 mg tablets in United States
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Standard
4 days ago
- Business Standard
Blue Jet Healthcare standalone net profit rises 141.32% in the June 2025 quarter
Sales rise 117.78% to Rs 354.76 croreNet profit of Blue Jet Healthcare rose 141.32% to Rs 91.17 crore in the quarter ended June 2025 as against Rs 37.78 crore during the previous quarter ended June 2024. Sales rose 117.78% to Rs 354.76 crore in the quarter ended June 2025 as against Rs 162.90 crore during the previous quarter ended June EndedJun. 2025Jun. 2024% 118 OPM %34.1127.17 -PBDT128.5652.95 143 PBT122.8649.47 148 NP91.1737.78 141 Powered by Capital Market - Live News
Economic Times
14-07-2025
- Economic Times
Sun Pharma settles litigation with Incyte Corp over hair loss drug Leqselvi
Synopsis Sun Pharmaceutical Industries has reached a settlement agreement with Incyte Corporation concerning Leqselvi, a drug for severe hair loss, leading to the dismissal of pending litigation in the US. Incyte has granted Sun a non-exclusive license for oral deuruxolitinib for specific non-oncology indications, including alopecia areata, in the US. Reuters Sun pharma logo( File photo) Sun Pharmaceutical Industries on Monday said it has inked a settlement pact with US-based Incyte Corporation regarding Leqselvi, a drug used for severe hair the terms of agreement, the parties will seek dismissal of the pending Leqselvi litigation in the US District Court for the District of New Jersey, and Sun and Incyte will mutually release each other of all claims that were raised or could have been raised in that litigation, the Mumbai-based drug major said in a statement. As a part of the agreement, Incyte has granted to Sun a limited, non-exclusive license to US Patent Nos. 9,662,335 and certain other related patents with respect to oral deuruxolitinib for certain agreed-upon non-hematology-oncology indications, including alopecia areata, in the US, it added. Sun will pay Incyte an upfront amount, plus ongoing royalty payments until the expiry of the patents, in exchange for the settlement and license, it stated. Other specific terms of the settlement and license agreement are confidential, it added. In a separate statement, the drug firm announced the launch of Leqselvi (8 mg) tablets in the US medication (deuruxolitinib) is indicated for the treatment of adults with severe alopecia areata."The launch of Leqselvi in the US brings an effective, new treatment option for severe alopecia areata to eligible patients and the healthcare providers who treat them," Richard Ascroft, CEO of Sun Pharma North America, said."As a company committed to launching new therapeutic options which address the unmet needs of patients, adding Leqselvi to our dermatology portfolio represents a key milestone for the business and an important advancement for the alopecia areata community," he added. Shares of Sun Pharma ended 0.54 per cent higher at Rs 1,681.45 apiece on the BSE.
The Hindu
14-07-2025
- The Hindu
Sun Pharma reaches settlement with Incyte Corporation, launches Leqselvi in U.S.
Sun Pharmaceutical Industries Ltd has announced that it has entered into a settlement and license agreement with Incyte Corporation regarding litigation related to LEQSELVI (deuruxolitinib). 'Under the terms of agreement, the parties will seek dismissal of the pending LEQSELVI litigation in the United States District Court for the District of New Jersey and Sun and Incyte will mutually release each other of all claims that were raised or could have been raised in that litigation,' Sun Pharma said in a statement. As a part of agreement, Incyte has granted to Sun a limited, non-exclusive license to U.S. Patent and certainother related patents with respect to oral deuruxolitinib for certain agreed-upon non-hematology-oncology indications including alopecia areata, in the U.S. Sun will pay to Incyte an upfront amount, plus ongoing royalty payments until the expiry of the patents, in exchange for the settlement and license. 'Other specific terms of the settlement and license agreement are Confidential,' Sun Pharma said. After the settlement was reached, Sun Pharma has announced the launch of LEQSELVI 8 mg tablet in the United States for the treatment of severe alopecia areata. 'The launch of LEQSELVI in the U.S. brings an effective, new treatment option for severe alopecia areata to eligible patients and the healthcare providers who treat them,' said Richard Ascroft, CEO, Sun Pharma North America.
